Compare
Viemed Healthcare, Inc. vs Progyny, Inc. vs Cryo Cell International Inc vs Marpai, Inc.
| Latest fiscal year | Viemed Healthcare, Inc. VMD | Progyny, Inc. PGNY | Cryo Cell International Inc CCEL | Marpai, Inc. MRAI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-11-30 | 2025-12-31 |
| Revenue | $270.28M | $1.29B | $31.57M | $18.10M |
| Revenue growth (YoY) | +20.5% | +10.4% | -1.3% | -35.8% |
| Gross margin | 57.5% | 23.6% | 76.6% (computed) | n/a |
| Operating margin | 8.5% | 6.6% | 1.5% | -74.9% |
| Net margin | 5.5% | 4.5% | -7.7% | -91.5% |
| Net income | $14.93M | $58.52M | -$2.43M | -$16.56M |
| EPS (Diluted) | $0.37 | $0.65 | -$0.30 | -$0.95 |
| Operating cash flow | $51.92M | $210.19M | $5.48M | -$7.45M |
| Free cash flow | $11.93M | $191.78M | $5.25M | n/a |
| Cash & equivalents | $13.50M | $112.24M | $319.0K | $133.0K |
| Total assets | $199.15M | $742.43M | $61.73M | $10.90M |
| Total liabilities | $55.63M | $226.39M | $80.33M | $43.47M |
| Shareholders' equity | $141.54M | $516.04M | -$18.61M | -$32.56M |
| Return on year-end equity | 10.6% | 11.3% | n/a | n/a |
| Shares outstanding | 38.02M | 83.37M | 8.06M | 24.04M |
Revenue, most recent five fiscal years
| Fiscal year | Viemed Healthcare, Inc. | Progyny, Inc. | Cryo Cell International Inc | Marpai, Inc. |
|---|---|---|---|---|
| Latest | $270.28M Ended 2025-12-31 | $1.29B Ended 2025-12-31 | $31.57M Ended 2025-11-30 | $18.10M Ended 2025-12-31 |
| 1 year earlier | $224.26M Ended 2024-12-31 | $1.17B Ended 2024-12-31 | $31.99M Ended 2024-11-30 | $28.17M Ended 2024-12-31 |
| 2 years earlier | $183.01M Ended 2023-12-31 | $1.09B Ended 2023-12-31 | $31.34M Ended 2023-11-30 | $37.16M Ended 2023-12-31 |
| 3 years earlier | $138.83M Ended 2022-12-31 | $786.91M Ended 2022-12-31 | $30.34M Ended 2022-11-30 | n/a |
| 4 years earlier | $117.06M Ended 2021-12-31 | $500.62M Ended 2021-12-31 | $28.88M Ended 2021-11-30 | n/a |